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Predictors of high on-aspirin platelet reactivity in 
elderly patients with coronary artery disease
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Objectives: Previous studies have illustrated the link between high on-aspirin platelet reactivity 
(HAPR) with increasing thrombotic risks. The aim of our study was to investigate relative risk 
factors of HAPR in elderly patients with coronary artery disease.
Methods: Elderly, hospitalized coronary artery disease patients on regular aspirin treatment were 
enrolled from January 2014 to September 2016. Medical records of each patient were collected, 
including demographic information, cardiovascular risk factors, concomitant drugs and routine 
biological parameters. Arachidonic acid (AA, 0.5 mg/mL) and adenosine diphosphate (ADP, 
5 µmol/L) induced platelet aggregation were measured via light transmission assay (LTA) to 
evaluate antiplatelet responses, referred as LTA–AA and LTA–ADP.
Results: A total of 275 elderly patients were included, with mean age of 77.2±8.1 years, and 
males accounted for 81.8%. HAPR was defined as LTA–AA in the upper quartile of the enrolled 
population. HAPR patients tended to have lower renal function (P=0.052). Higher serum uric 
acid (SUA) level, as well as lower platelet count, hemoglobin and hematocrit were observed 
in HAPR patients, with a higher proportion of diuretics use (P,0.05). Multivariate analysis 
revealed that SUA (OR: 1.004, 95% CI: 1.000–1.007, P=0.048), platelet count (OR: 0.994, 
95% CI: 0.989–1.000, P=0.045), hematocrit (OR: 0.921, 95% CI: 0.864–0.981, P=0.011) and 
concomitant P2Y12 receptor inhibitors use (OR: 1.965, 95% CI: 1.075–3.592, P=0.028) were 
correlated with HAPR. Spearman’s correlation analysis demonstrated an inverse association 
of LTA–AA with hematocrit (r=-0.234, P,0.001), hemoglobin (r=-0.209, P,0.001) and 
estimated glomerular filtration rate (r=-0.132, P=0.031).
Conclusion: SUA, platelet count, hematocrit and P2Y12 receptor inhibitors use were inde-
pendently correlated with HAPR. These parameters might provide novel therapeutic targets 
for optimizing antiplatelet therapy.
Keywords: aspirin, platelet reactivity, elderly, risk factors,coronary artery disease
Introduction
Thrombosis, considered as pathological hemostasis, is one of the severe complications 
for coronary artery disease (CAD), which poses a great threat to public health. Platelet 
activation plays crucial roles in the process of thrombosis. For one thing, during the 
early stage of thrombosis, vascular injury initiates the recruitment of platelets to the 
damaged sites, then the activated platelets adhere to the vessel wall and release platelet 
agonists, which promote additional platelet activation and aggregation. For another, 
platelets exert procoagulant effects and release mediators that support the recruitment 
of leukocytes.1,2 In addition, recent studies revealed that platelet-derived mRNAs, 
miRNAs and exosomes are also involved in thrombus formation.3
Aspirin, exerting inhibitory effects on platelet activation by acetylating the serine 
529 residue of cyclooxygenase (COX), reduces the risk of myocardial infarction 
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and stroke, and is thus widely used in the prevention and 
treatment of cardiovascular diseases.4,5 However, individual 
variations in the platelet response to aspirin limits its use in 
some patients, including patients who experience ischemic 
events despite regular aspirin therapy.6–8
High on-aspirin platelet reactivity (HAPR) is defined as 
insufficient inhibition of platelet activation in patients on 
regular aspirin treatment. As a consequence, aspirin fails to 
prevent thrombotic complications in a significant proportion 
of patients, in the range of 7%–20% of adults.9,10 Several 
mechanisms of HAPR have been put forward, such as the 
decreased biological availability, drug–drug interactions, 
inadequate doses or poor compliance, reduced absorption due 
to advanced age or concurrent proton pump inhibitors (PPIs), 
non-platelet thromboxane A2 (TXA2) synthesis, accelerated 
platelet turnover, polymorphism of COX/glycoprotein IIβ/
IIIα (GPIIβ/IIIα)/P2Y12 receptors/collagen receptors and 
others.7,11,12
The link between HAPR with increasing risk of isch-
emic events has been demonstrated in previous studies.13,14 
A number of platelet function tests (PFTs) have been 
developed to distinguish HAPR patients, intending to reduce 
thrombotic risks as well as to guide individual treatment,15,16 
among which light transmission assay (LTA) was regarded 
as the traditional “gold standard” of PFTs. Using dif-
ferent platelet agonists, such as arachidonic acid (AA), 
adenosine diphosphate (ADP), collagen and epinephrine, 
platelet inhibition due to aspirin or thienopyridines could 
be distinguished. However, controversies still existed 
in optimal cut-off for aspirin response, which should be 
capable of predicting both thrombotic events and bleeding 
complications.17
Older age was associated with an increasing incidence 
of high platelet reactivity (HPR) in patients receiving anti-
platelet therapy, which might partially elucidate the relatively 
higher thrombosis risks and poorer prognosis in this par-
ticular population.18,19 In this study, we aimed to investigate 
potential risk factors for HAPR in elderly CAD patients 
(aged .60 years), thus identifying “at-risk” patients and 
promoting the optimization of antiplatelet therapy.
Methods and materials
study design
Elderly patients on regular aspirin treatment (100 mg/d), 
hospitalized in the Department of Geriatrics of Peking 
University First Hospital were enrolled from January 2014 
to September 2016. Inclusion criteria were as follows:
1. Age: .60 years.
2. Presence of at least one of the following: stable angina 
pectoris; acute coronary syndrome (ACS); previous per-
cutaneous coronary intervention (PCI); coronary artery 
bypass graft; confirmed coronary atherosclerotic plaques 
via computed tomography angiography or coronary 
angiography.
3. Platelet count in the range between 75×109/L and 
600×109/L.
Patients were excluded when there existed contrain-
dications for aspirin, concomitant with non-steroidal 
anti-inflammatory drugs, GPIIβ/IIIα receptor inhibitors, 
Vitamin K antagonists or novel anticoagulants; patients with 
severe renal or liver dysfunction, peptic ulcer or history of 
gastrointestinal hemorrhage were excluded.
This study complied with the Declaration of Helsinki, 
and the protocol was approved by the Ethical Review Com-
mittee of Peking University First Hospital. Written informed 
consent was obtained from all the enrolled participants.
light transmission assay
All patients were on aspirin 100 mg/day treatment for at 
least 1 week before evaluating platelet function by LTA. 
LTA using AA, 0.5 mg/mL induced platelet aggregation 
(LTA–AA) was measured in order to evaluate aspirin 
responses as described.20,21 Peripheral blood samples were 
drawn in a sodium citrate tube (1:9), and all measure-
ments were conducted within 2 hours. Platelet-rich plasma 
(PRP) and platelet-poor plasma (PPP), used as reference, 
were prepared through centrifugation at separate speeds 
(200× g 10 min for PRP; 2,000× g 10 min for PPP). AA-
induced platelet aggregation was performed using an 
LBY-NJ4 platelet aggregometer (PRECIL, Beijing, China). 
The percentage of platelet aggregation was defined as the 
maximal light transmittance after AA addition. Besides this, 
ADP, 5 µmol/L induced platelet aggregation (LTA–ADP) 
was also measured to exclude patients with poor response 
to thienopyridines.22,23 Platelet aggregation results were 
further normalized based on platelet counts of each blood 
sample to mitigate bias.
hospitalization records collection
For each patient, detailed medical records during the hospi-
talization were obtained from the electronic system, including 
age, gender, cardiovascular disease status, cardiovascular risk 
factors, combined drugs, co-morbidities, routine biological 
parameters such as routine blood test, glucose, coagulation 
function, renal or liver function parameters, uric acid, lipids 
and others (Table 1).
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statistical analysis
Continuous variables were expressed as mean ± SD or median 
(range), while categorical variables were described as frequency 
and percentage. Conformity to normal distribution was evalu-
ated for continuous variables using both Kolmogorov–Smirnov 
and Shapiro–Wilk tests. One-way analysis of variance test or 
nonparametric Kruskal–Wallis test was used to make com-
parisons for continuous variables, while chi-square or Fisher 
exact test was applied for categorical variables. Chi-square and 
linear trend test was performed to make comparison for age 
composition in patients with different platelet reactivity status. 
Receiver operating characteristic (ROC) curve and multivariate 
logistic regression analysis was performed to investigate risk 
factors for HAPR, and Spearman’s correlation test was used 
to identify the factors correlated with LTA–AA. A 2-tailed 
P-value ,0.05 was considered as statistically significant for 
all analysis executed. Statistical analysis was carried out using 
SPSS version 14.0 software (SPSS Inc., Chicago, IL, USA).
Table 1 Clinical features in patients with different platelet reactivity status
Clinical features LAPR (n=69) MAPR (n=138) HAPR (n=68) P-value
Age (years) 76.0±8.6 77.2±8.3 78.4±7.2 0.266
Female gender, n (%) 17 (24.6) 24 (17.4) 9 (13.2) 0.217
BMI (kg/m2) 24.9±3.7 24.5±3.2 24.5±3.0 0.596
Previous PCI, n (%) 38 (55.1) 80 (58.0) 38 (55.9) 0.912
hypertension, n (%) 51 (73.9) 102 (73.9) 53 (38.4) 0.798
Diabetes, n (%) 28 (40.6) 59 (42.8) 33 (48.5) 0.617
Ischemic cerebrovascular disease, n (%) 14 (20.3) 42 (30.4) 24 (35.3) 0.137
hyperlipidemia, n (%) 57 (82.6) 115 (83.3) 59 (86.8) 0.767
Peripheral artery disease, n (%) 57 (82.6) 111 (80.4) 54 (79.4) 0.887
Current smoking, n (%) 13 (18.8) 16 (11.6) 9 (13.2) 0.358
lVeF (%) 60.0 (32.0–70.0) 61.0 (40.0–80.0) 61.0 (43.0–77.0) 0.861
egFr (ml/min) 66.2±16.9 65.0±15.2 59.8±18.2 0.052
25-(Oh)-D (pg/ml) 40.5±17.0 40.6±16.2 43.4±16.6 0.410
hbA1c (%) 6.0 (5.4–9.0) 6.0 (5.2–9.8) 6.1 (5.2–8.4) 0.478
hcy (µmol/l) 14.7±5.7 14.2±6.1 13.2±4.3 0.185
hsCrP (mg/l) 1.9 (0.0–16.1) 2.8 (0.0–31.5) 2.5 (0.0–19.7) 0.951
Tg (mmol/l) 1.2 (0.4–3.5) 1.4 (0.4–5.6) 1.2 (0.4–4.8) 0.253
TChO (mmol/l) 3.4 (2.4–5.1) 3.4 (1.7–6.4) 3.4 (2.0–5.9) 0.735
hDl-C (mmol/l) 1.0 (0.7–1.7) 1.0 (0.4–4.8) 1.0 (0.5–2.1) 0.243
lDl-C (mmol/l) 1.9 (0.5–3.0) 1.8 (0.9–5.2) 1.9 (1.1–4.3) 0.418
sUA (µmol/l) 344.2±69.5 337.9±85.2 368.0±89.7 0.010*
PlT ×109/l 202.9±93.6 186.6±53.2 172.4±51.2 0.025*
MPV (fl) 8.5 (6.9–13.8) 8.4 (6.2–12.4) 8.6 (7.0–11.3) 0.651
hb (g/l) 134.6±16.6 132.1±16.1 126.7±17.4 0.033*
hct (%) 39.0±4.6 38.1±4.6 36.4±5.0 0.005**
PT (s) 10.9±1.5 11.2±2.9 11.5±3.0 0.981
APTT (s) 32.7±5.6 31.9±4.9 32.3±4.7 0.804
FIB-c (g/l) 2.9 (1.8–5.5) 2.8 (1.7–4.4) 2.9 (1.3–6.1) 0.552
FDP (mg/l) 1.3 (0.0–7.4) 1.5 (0.0–31.4) 1.8 (0.0–11.3) 0.112
Thienopyridines, n (%) 29 (42.0) 69 (50.0) 41 (60.3) 0.099
statins, n (%) 64 (92.7) 130 (94.2) 65 (95.6) 0.778
ACeI/ArB, n (%) 29 (18.8) 60 (20.3) 35 (20.6) 0.442
β-blockers, n (%) 50 (72.4) 94 (68.1) 49 (72.1) 0.753
CCB, n (%) 27 (39.1) 53 (38.4) 29 (42.6) 0.839
Diuretics, n (%) 8 (11.6) 18 (13.0) 17 (25.0) 0.048*
nitrates, n (%) 25 (36.2) 55 (39.9) 26 (38.2) 0.878
hypoglycemics, n (%) 19 (27.5) 44 (31.9) 23 (33.8) 0.710
PPI, n (%) 21 (30.4) 43 (31.2) 24 (35.3) 0.796
Notes: Values are mean ± sD or median (range) unless stated otherwise. *P,0.05, **P,0.01.
Abbreviations: ACeI, angiotensin-converting enzyme inhibitor; APTT, activated prothromboplastin time; ArB, angiotensin receptor antagonist; BMI, body mass 
index; CCB, calcium channel blockers; eGFR, estimated glomerular filtration rate; FDP, fibrin degradation product; Fib-c, Fibrinogen c; HAPR, high on-aspirin platelet 
reactivity; hb, hemoglobin; hbA1c, hemoglobin A1c; hct, hematocrit; hcy, homocysteine; hDl-C, high density lipoprotein cholesterol; hsCrP, hypersensitive C reactive 
protein; lAPr, low on-aspirin platelet reactivity; lDl-C, low density lipoprotein cholesterol; lVeF, left ventricular ejection fraction; MAPr, moderate on-aspirin platelet 
reactivity; MPV, mean platelet volume; PCI, percutaneous coronary intervention; PlT, platelet count; PPI, proton pump inhibitors; PT, prothrombin time; sUA, serum uric 
acid; TChO, total cholesterol; Tg, triglycerides.
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Results
enrollment
A total of 289 elderly CAD patients on regular aspirin 
treatment were enrolled, but 14 patients with high on- 
clopidogrel platelet reactivity (5 µmol/L ADP-induced 
platelet aggregation more than 50%) were excluded to avoid 
bias, resulting in a total of 275 elderly CAD patients with 
the mean age of 77.2±8.1 years. Males accounted for 81.8% 
(225 of 275), and 156 of the 275 CAD patients (56.7%) 
had received PCI previously. The enrollment flowchart is 
shown in Figure S1.
Distribution of platelet aggregation
Light transmission assay of AA-induced platelet aggrega-
tion (LTA–AA) was measured to evaluate aspirin response, 
with the quartiles 9.54%, 11.63% and 13.93% of residual 
platelet aggregation respectively. HAPR was defined as 
LTA–AA in the upper quartile, that is, more than 13.93% 
residual platelet aggregation (n=68). Meanwhile, low on-
aspirin platelet reactivity (LAPR) was defined as LTA–AA 
in the lower quartile of the enrolled population (#9.54%, 
n=69). The remaining 138 patients in the middle 2 quartiles 
were assigned into moderate on-aspirin platelet reactivity 
(MAPR) group.
As shown in Figure 1A, age composition varied among 
LAPR, MAPR and HAPR patients, and the proportion of 
senile patients (aged $80 years) increased gradually, from 
LAPR group to HAPR group (P for linear trend =0.046). 
Distribution of LTA–AA and LTA–ADP in patients receiving 
dual antiplatelet therapy (DAPT) is shown in Figure 1B.
Clinical features of hAPr
Patients were divided into 3 groups, HAPR, MAPR and 
LAPR, according to quartiles of LTA–AA. Comparisons 
were made in terms of age, gender composition, cardiovascu-
lar risk factors, co-morbidities, routine biological parameters 
and concomitant drugs.
As shown in Table 1, HAPR patients had a tendency 
toward reduced renal function (P=0.052). Higher serum uric 
acid (SUA), as well as lower platelet count, hematocrit and 
hemoglobin were observed in HAPR patients (P,0.05). In 
terms of combined drugs, diuretics use was more frequently 
prescribed in HAPR patients (P,0.05).
The cut-off for hyperuricemia in the elderly was defined 
as the SUA concentration .7 mg/dL (416.5 mmol/L).24 
Patients who met that criteria (n=47) for hyperuricemia were 
more common in HAPR patients, when compared with non-
HAPR patients (14.5%, 12.3%, 29.4% for LAPR, MAPR 
and HAPR, P=0.023).
Multivariate regression analysis
Predictive value for HAPR of each of the variables listed in 
Table 1 with a P-value ,0.10 were evaluated using ROC 
curve, including SUA, platelet count, estimated glomerular 
filtration rate (eGFR), hemoglobin and hematocrit. Areas 
under the ROC curve are exhibited in Table S1. Furthermore, 
a combination of these variables had an improved predictive 
value when compared with each variable alone (area under 
the curve [AUC]: 0.661, 95% CI: 0.581–0.740, P,0.001).
To investigate related factors for HAPR, multivariate 
regression analysis was performed. Previously reported 
Figure 1 light transmission assay.
Notes: (A) Patients were divided into 3 groups according to the quartile of lTA–AA, and age composition varied among lAPr, MAPr and hAPr patients. The percentage 
of senile patients (aged more than or equal to 80 years) increased gradually, from lAPr group to hAPr group (P for linear trend =0.046). (B) The distribution of lTA–AA 
and lTA–ADP in patients receiving dual antiplatelet therapy. The vertical dotted line indicates the cut-off of hAPr (13.93%), while the horizontal line marked the cut-off for 
poor clopidogrel response (50%). hAPr (lTA–AA .13.93%, n=68); lAPr (lTA–AA #9.54%, n=69); MAPr (9.54%, lTA–AA #13.93%, n=138).
Abbreviations: ADP, adenosine diphosphate; hAPr, high on-aspirin platelet reactivity; lTA–AA, light transmission assay-arachidonic acid; lAPr, low on-aspirin platelet 
reactivity; MAPr, moderate on-aspirin platelet reactivity.
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variables such as age, gender, type 2 diabetes mellitus, current 
smoking and serum lipids were considered.25–27 Variables 
listed in Table 1 with a P-value ,0.10 were also selected, 
including eGFR, SUA, platelet count, hemoglobin, hemat-
ocrit, concomitant P2Y12 receptor inhibitors and diuretics 
use. Table 2 lists the variables included in the equation at 
the last step, and all P-values have been adjusted for age 
and gender. It was revealed that SUA (OR: 1.004, 95% CI: 
1.000–1.007, P=0.048), platelet count (OR: 0.994, 95% 
CI: 0.989–1.000, P=0.045), hematocrit (OR: 0.921, 95% 
CI: 0.864–0.981, P=0.011) and concomitant P2Y12 receptor 
inhibitors use (OR: 1.965, 95% CI: 1.075–3.592, P=0.028) 
were independently correlated with HAPR.
Spearman’s correlation analysis was performed to evalu-
ate the correlation between LTA–AA and these variables 
with a P-value ,0.10. As shown in Figure 2, hemoglobin 
(r=-0.209, P,0.001), hematocrit (r=-0.234, P,0.001) and 
eGFR (r=-0.132, P=0.031) were negatively associated with 
LTA–AA.
Discussion
Advanced age is associated with higher risk of throm-
botic complications, with increased mortality and worse 
prognosis,28,29 which might be partly due to the increasing 
occurrence of HPR in this population.18,30 In our study, the 
percentage of senile patients gradually increased from LAPR 
to HAPR group. The relatively higher proportion of senile 
patients in HAPR group might be due to declined absorption 
of aspirin, drug–drug interactions and age-related hemody-
namic changes in the elderly. As the link between HAPR with 
Figure 2 spearman’s correlation analysis.
Notes: (A) hematocrit (r=-0.234, P,0.001) was negatively associated with lTA–AA. (B) hemoglobin (r=-0.209, P,0.001) was inversely correlated with lTA–AA. (C) egFr 
(r=-0.132, P=0.031) was inversely correlated with lTA–AA.
Abbreviations: eGFR, estimated glomerular filtration rate; Hb, hemoglobin; Hct, hematocrit; LTA–AA, light transmission assay-arachidonic acid.
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Table 2 risk factors associated with hAPr
Variables B SE Wald P-value OR 95% Lower 95% Upper
sUA 0.00 0.002 3.920 0.048* 1.004 1.000 1.007
PlT -0.01 0.003 4.011 0.045* 0.994 0.989 1.000
hct -0.08 0.032 6.515 0.011* 0.921 0.864 0.981
Diuretics 0.64 0.379 2.867 0.090 1.900 0.904 3.994
P2Y12 receptor inhibitors 0.68 0.308 4.820 0.028* 1.965 1.075 3.592
Constant 1.24 1.478 0.703 0.402 3.453
Note: *P,0.05.
Abbreviations: hAPr, high on-aspirin platelet reactivity; hct, hematocrit; Or, odds ratio; PlT, platelet count; se, standard error; sUA, serum uric acid.
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cardiovascular events has been substantially illustrated, it is 
crucial to reveal predictors of HAPR and uncover potential 
mechanisms, in order to identify at-risk patients and to opti-
mize antiplatelet therapy, especially in the elderly.
In our study, HAPR patients tended to have reduced renal 
function, and Spearman’s correlation analysis confirmed an 
inverse association between LTA–AA and eGFR. Similarly, 
Blann et al observed a weak relationship between lower eGFR 
and HAPR, regardless of the method for platelet reactivity 
evaluation. What is more, eGFR even showed an inverse 
correlation with platelet expression of CD62P.31 Aksu et al 
observed higher incidence of HAPR in patients with severe 
chronic kidney disease (CKD), but not in mild or moder-
ate CKD. HAPR might contribute to the increasing risk of 
cardiovascular complications in patients with declined renal 
function.32 However, Tello–Montoliu et al failed to track the 
link between antiplatelet response with renal dysfunction 
in non-diabetic patients with CAD.33 Our study excluded 
patients with severe CKD, thus minimizing the impact.
In our study, higher SUA level, as well as higher incidence 
of hyperuricemia was observed in HAPR patients. Previous 
studies reported the increasing risk of recurrent gout attacks 
in patients on low-dose aspirin.34 However, the link between 
SUA with aspirin response in the elderly has not been reported 
before. In the Nardin et al study, SUA level increased in 
patients receiving aspirin in combination with ticagrelor, but 
not in those with clopidogrel. However, their work failed 
to confirm effects of SUA on residual platelet reactivity.35 
Similarly, Barbieri et al did not observe an association between 
SUA and HAPR.36 However, a weak correlation between 
HAPR with SUA was shown in our enrolled patients, and 
higher SUA level might potentially indicate the relatively poor 
response to aspirin. A possible explanation was that elevation 
of uric acid promotes the formation of a pro-inflammatory and 
prothrombotic state, with an increase in non-platelet TXA2 
synthesis, thus leading to insufficient platelet inhibition.37
Elderly HAPR patients had lower platelet count, when 
compared with non-HAPR patients. Likewise, platelet count 
was weakly correlated with HAPR in our study. It was 
conventionally thought that platelet counts might influence 
the results of platelet aggregation studies. However, recent 
studies revealed that LTA is not sensitive to platelet count 
changes, at least within a broad range of 150–600×109/L.38,39 
In ADAPT–DES (Assessment of Dual AntiPlatelet Therapy 
with Drug-Eluting Stents) study, lower platelet count was 
associated with higher P2Y12 reaction units (PRU), but 
after multivariate adjustment, higher platelet count was 
independently associated with increased thrombosis risks.40 
It was also reported that aspirin might promote platelet 
apoptosis via several mechanisms, including the activation 
of p38 map kinase (MAPK), protein kinase C/B (PKC/PKB) 
and caspase-3, inhibition of proteasome function, triggering 
phosphatidylserine externalization and so forth.41–43
An inverse association of LTA–AA with hemoglobin 
and hematocrit was observed in our study. Previous studies 
reported the negative association between hematocrit or 
hemoglobin with VerifyNow assays or multiple electronic 
assay results, but not with LTA. In Voisin et al study, while 
PRU significantly declined, hematocrit and hemoglobin 
increased, but the percentage of platelet inhibition did not 
vary.44 In Pendyala et al study, lower baseline hematocrit was 
linked with HPR evaluated by the VerifyNow assay.45 Kim 
et al confirmed an inverse correlation between VerifyNow 
assay results with hematocrit (r=-0.409, P=0.001), and after 
adjustment, anemia was an independent risk factor for HPR.46 
A possible explanation is that hematocrit changes might 
influence calcium concentration in citrated blood used for 
PFTs. Thus, Kakouros et al developed a formula for PRU 
adjustment according to hematocrit.47,48
Concomitant drugs might influence antiplatelet effects as 
well. Our study revealed the proportion of diuretic use was 
higher in HAPR patients when compared with non-HAPR 
patients. However, it is inadequate to establish a causal 
relationship, and the potential mechanisms warrant further 
study. Further, concomitant P2Y12 receptor inhibitor use was 
correlated with HAPR, possibly due to the tendency of more 
P2Y12 receptor inhibitor use in patients with poor aspirin 
response to obtain sufficient platelet inhibition. Furthermore, 
previous studies reported possible effects of PPIs, calcium 
channel blockers (CCBs) or statins on antiplatelet responses, 
while controversies existed. In Liu et al, esomeprazole or 
rabeprazole use did not affect antiplatelet response after 
initiation of DAPT for 30 days.49 ADAPT–DES study dem-
onstrated the interaction between combined PPIs use with 
clopidogrel (OR: 1.38, 95% CI: 1.25–1.52, P,0.001).50 
Tsukahara et al reported that CCB use was associated with 
higher incidence of HPR (OR: 1.93, 95% CI: 1.18–3.18, 
P,0.05).51 In Gremmel et al, co-administration with CCB 
was an independent risk factor of HPR, based on both LTA 
assay and VerifyNow assay.52 In terms of statins effects, it 
was reported that switching to a non-CYP3A4 metabolized 
statin might minimize drug–drug interactions and improve 
antiplatelet responses.53 However, Malmstrom et al revealed 
that lipid-lowering treatments did not exert additional 
inhibitory effects on platelets in CAD patients with impaired 
glucose tolerance.54
The present studies have some advantages. First, the 
mean age of our enrolled patients were 77.2 years, higher 
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than most previous studies, which focused on HAPR. As 
older age has been recognized as a crucial risk factor for 
HAPR, investigating predictors of HAPR in this popula-
tion might promote the optimization of antiplatelet therapy 
and uncover potential mechanisms. Further, ADP-induced 
platelet aggregation was used to exclude patients with poor 
response to thienopyridines, thus minimizing interference 
factors. Furthermore, all LTA assays in this study were per-
formed by skilled technicians in our clinical laboratory, and 
results were normalized according to platelet counts.
Nevertheless, there are a few limitations. Mainly, this 
is a single-center study and other PFTs such as VerifyNow 
aspirin, multiple electrode platelet aggregometry or PFA-100 
were not performed simultaneously.
In conclusion, elderly HAPR patients tended to have 
reduced renal function, higher SUA level as well as lower 
platelet count, hemoglobin and hematocrit. Platelet count, 
SUA, hematocrit and concomitant P2Y12 receptor inhibitors 
use were independently correlated with HAPR. These param-
eters might provide novel therapeutic targets for optimizing 
antiplatelet therapy.
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Table S1 Predictive value for hAPr (rOC curve)
Variables AUC P-value 95% Lower 95% Upper
sUA 0.625 0.002** 0.545 0.706
PlT 0.580 0.052 0.499 0.662
egFr 0.593 0.024* 0.511 0.676
hb 0.578 0.060 0.500 0.656
hct 0.595 0.021* 0.518 0.673
Combination (sUA + PlT + egFr + hb + hct) 0.661 ,0.001*** 0.581 0.740
Notes: *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: AUC, area under the curve; eGFR, estimated glomerular filtration rate; HAPR, high on-aspirin platelet reactivity; Hb, hemoglobin; Hct, hematocrit; PLT, 
platelet count; rOC, receiver operator characteristic; sUA, serum uric acid.
Figure S1 Flowchart of the study.
Abbreviations: CAD, coronary artery disease; hAPr, high on-aspirin platelet reactivity; lAPr, low on-aspirin platelet reactivity; lTA–AA, light transmission assay-
arachidonic acid; MAPr, moderate on-aspirin platelet reactivity.
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